Global Pharmacogenetic Testing Market Analysis

TABLE 1 GLOBAL PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 2 GLOBAL WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 3 GLOBAL WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 4 GLOBAL WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 5 GLOBAL WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 6 GLOBAL ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 7 GLOBAL ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 8 GLOBAL SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 9 GLOBAL SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 10 GLOBAL PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)

TABLE 11 GLOBAL CYP2C19 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 12 GLOBAL CYP2D6 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 13 GLOBAL CYP2C9 AND VKORC1 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 14 GLOBAL CYP1A2 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 15 GLOBAL HLA-B*1502 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 16 GLOBAL HLA-B*5701 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 17 GLOBAL CYP2D IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 18 GLOBAL OPRM1 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 19 GLOBAL ONCOTYPE DX* AND MAMMAPRINT IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 20 GLOBAL DRD3 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 21 GLOBAL D4D4 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 22 GLOBAL SLC6A4 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 23 GLOBAL HTR2A/C IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 24 GLOBAL TMPT IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 25 GLOBAL OTHERS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 26 GLOBAL PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 27 GLOBAL PRESCRIPTION DRUGS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 28 GLOBAL NUTRACEUTICALS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 29 GLOBAL RECREATIONAL DRUGS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 30 GLOBAL HERBAL SUPPLEMENTS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 31 GLOBAL VITAMINS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 32 GLOBAL OVER-THE-COUNTER MEDICATIONS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 33 GLOBAL PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)

TABLE 34 GLOBAL BLOOD IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 35 GLOBAL SALIVA IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 36 GLOBAL PHARMACOGENETIC TESTING MARKET, BY THERPAEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 37 GLOBAL CARDIOLOGY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 38 GLOBAL GASTROENTEROLOGY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 39 GLOBAL ANESTHESIOLOGY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 40 GLOBAL GENOMICS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 41 GLOBAL ENDOCRINOLOGY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 42 GLOBAL IMMUNOLOGY & HYPERSENSITIVITY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 43 GLOBAL DERMATOLOGY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 44 GLOBAL GYNECOLOGY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 45 GLOBAL ONCOLOGY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 46 GLOBAL NEUROLOGY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 47 GLOBAL OTHERS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 48 GLOBAL PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 49 GLOBAL CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 50 GLOBAL CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 51 GLOBAL DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 52 GLOBAL DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 53 GLOBAL DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 54 GLOBAL DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 55 GLOBAL PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 56 GLOBAL HEALTHCARE PROVIDERS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 57 GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 58 GLOBAL RESEARCH CENTRES AND ACADEMIC INSTITUTES IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 59 GLOBAL OTHERS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 60 GLOBAL PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION)

TABLE 61 GLOBAL HOSPITAL PHARMACY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 62 GLOBAL RETAIL PHARMACIES IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 63 GLOBAL MAIL-ORDER PHARMACIES IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 64 GLOBAL DIRECT-TO-CUSTOMER SERVICES IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 65 GLOBAL PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 66 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 67 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 68 NORTH AMERICA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 69 NORTH AMERICA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 70 NORTH AMERICA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 71 NORTH AMERICA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 72 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)

TABLE 73 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 74 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)

TABLE 75 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 76 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 77 NORTH AMERICA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 78 NORTH AMERICA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 79 NORTH AMERICA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 80 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 81 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 82 U.S. PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 83 U.S. WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 84 U.S. WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 85 U.S. ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 86 U.S. SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 87 U.S. PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)

TABLE 88 U.S. PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 89 U.S. PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)

TABLE 90 U.S. PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 91 U.S. PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 92 U.S. CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 93 U.S. DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 94 U.S. DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 95 U.S. PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 96 U.S. PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 97 CANADA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 98 CANADA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 99 CANADA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 100 CANADA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 101 CANADA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 102 CANADA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)

TABLE 103 CANADA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 104 CANADA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)

TABLE 105 CANADA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 106 CANADA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 107 CANADA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 108 CANADA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 109 CANADA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 110 CANADA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 111 CANADA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 112 MEXICO PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 113 MEXICO WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 114 MEXICO WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 115 MEXICO ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 116 MEXICO SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 117 MEXICO PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)

TABLE 118 MEXICO PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 119 MEXICO PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)

TABLE 120 MEXICO PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 121 MEXICO PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 122 MEXICO CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 123 MEXICO DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 124 MEXICO DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 125 MEXICO PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 126 MEXICO PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 127 EUROPE PHARMACOGENETIC TESTING MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 128 EUROPE PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 129 EUROPE WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 130 EUROPE WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 131 EUROPE ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 132 EUROPE SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 133 EUROPE PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)

TABLE 134 EUROPE PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 135 EUROPE PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)

TABLE 136 EUROPE PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 137 EUROPE PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 138 EUROPE CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 139 EUROPE DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 140 EUROPE DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 141 EUROPE PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 142 EUROPE PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 143 GERMANY PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 144 GERMANY WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 145 GERMANY WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 146 GERMANY ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 147 GERMANY SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 148 GERMANY PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)

TABLE 149 GERMANY PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 150 GERMANY PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)

TABLE 151 GERMANY PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 152 GERMANY PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 153 GERMANY CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 154 GERMANY DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 155 GERMANY DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 156 GERMANY PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 157 GERMANY PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 158 FRANCE PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 159 FRANCE WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 160 FRANCE WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 161 FRANCE ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 162 FRANCE SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 163 FRANCE PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)

TABLE 164 FRANCE PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 165 FRANCE PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)

TABLE 166 FRANCE PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 167 FRANCE PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 168 FRANCE CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 169 FRANCE DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 170 FRANCE DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 171 FRANCE PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 172 FRANCE PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 173 U.K. PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 174 U.K. WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 175 U.K. WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 176 U.K. ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 177 U.K. SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 178 U.K. PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)

TABLE 179 U.K. PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 180 U.K. PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)

TABLE 181 U.K. PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 182 U.K. PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 183 U.K. CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 184 U.K. DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 185 U.K. DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 186 U.K. PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 187 U.K. PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 188 ITALY PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 189 ITALY WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 190 ITALY WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 191 ITALY ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 192 ITALY SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 193 ITALY PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)

TABLE 194 ITALY PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 195 ITALY PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)

TABLE 196 ITALY PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 197 ITALY PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 198 ITALY CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 199 ITALY DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 200 ITALY DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 201 ITALY PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 202 ITALY PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 203 SPAIN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 204 SPAIN WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 205 SPAIN WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 206 SPAIN ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 207 SPAIN SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 208 SPAIN PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)

TABLE 209 SPAIN PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 210 SPAIN PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)

TABLE 211 SPAIN PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 212 SPAIN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 213 SPAIN CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 214 SPAIN DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 215 SPAIN DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 216 SPAIN PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 217 SPAIN PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 218 RUSSIA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 219 RUSSIA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 220 RUSSIA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 221 RUSSIA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 222 RUSSIA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 223 RUSSIA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)

TABLE 224 RUSSIA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 225 RUSSIA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)

TABLE 226 RUSSIA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 227 RUSSIA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 228 RUSSIA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 229 RUSSIA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 230 RUSSIA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 231 RUSSIA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 232 RUSSIA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 233 TURKEY PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 234 TURKEY WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 235 TURKEY WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 236 TURKEY ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 237 TURKEY SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 238 TURKEY PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)

TABLE 239 TURKEY PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 240 TURKEY PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)

TABLE 241 TURKEY PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 242 TURKEY PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 243 TURKEY CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 244 TURKEY DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 245 TURKEY DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 246 TURKEY PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 247 TURKEY PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 248 BELGIUM PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 249 BELGIUM WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 250 BELGIUM WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 251 BELGIUM ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 252 BELGIUM SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 253 BELGIUM PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)

TABLE 254 BELGIUM PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 255 BELGIUM PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)

TABLE 256 BELGIUM PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 257 BELGIUM PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 258 BELGIUM CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 259 BELGIUM DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 260 BELGIUM DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 261 BELGIUM PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 262 BELGIUM PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 263 NETHERLANDS PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 264 NETHERLANDS WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 265 NETHERLANDS WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 266 NETHERLANDS ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 267 NETHERLANDS SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 268 NETHERLANDS PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)

TABLE 269 NETHERLANDS PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 270 NETHERLANDS PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)

TABLE 271 NETHERLANDS PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 272 NETHERLANDS PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 273 NETHERLANDS CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 274 NETHERLANDS DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 275 NETHERLANDS DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 276 NETHERLANDS PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 277 NETHERLANDS PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 278 SWITZERLAND PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 279 SWITZERLAND WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 280 SWITZERLAND WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 281 SWITZERLAND ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 282 SWITZERLAND SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 283 SWITZERLAND PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)

TABLE 284 SWITZERLAND PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 285 SWITZERLAND PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)

TABLE 286 SWITZERLAND PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 287 SWITZERLAND PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 288 SWITZERLAND CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 289 SWITZERLAND DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 290 SWITZERLAND DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 291 SWITZERLAND PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 292 SWITZERLAND PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 293 REST OF EUROPE PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 294 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 295 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 296 ASIA-PACIFIC WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 297 ASIA-PACIFIC WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 298 ASIA-PACIFIC ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 299 ASIA-PACIFIC SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 300 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)

TABLE 301 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 302 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)

TABLE 303 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 304 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 305 ASIA-PACIFIC CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 306 ASIA-PACIFIC DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 307 ASIA-PACIFIC DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 308 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 309 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 310 JAPAN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 311 JAPAN WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 312 JAPAN WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 313 JAPAN ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 314 JAPAN SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 315 JAPAN PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)

TABLE 316 JAPAN PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 317 JAPAN PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)

TABLE 318 JAPAN PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 319 JAPAN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 320 JAPAN CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 321 JAPAN DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 322 JAPAN DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 323 JAPAN PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 324 JAPAN PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 325 CHINA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 326 CHINA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 327 CHINA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 328 CHINA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 329 CHINA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 330 CHINA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)

TABLE 331 CHINA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 332 CHINA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)

TABLE 333 CHINA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 334 CHINA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 335 CHINA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 336 CHINA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 337 CHINA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 338 CHINA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 339 CHINA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 340 SOUTH KOREA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 341 SOUTH KOREA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 342 SOUTH KOREA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 343 SOUTH KOREA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 344 SOUTH KOREA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 345 SOUTH KOREA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)

TABLE 346 SOUTH KOREA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 347 SOUTH KOREA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)

TABLE 348 SOUTH KOREA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 349 SOUTH KOREA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 350 SOUTH KOREA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 351 SOUTH KOREA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 352 SOUTH KOREA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 353 SOUTH KOREA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 354 SOUTH KOREA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 355 INDIA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 356 INDIA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 357 INDIA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 358 INDIA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 359 INDIA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 360 INDIA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)

TABLE 361 INDIA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 362 INDIA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)

TABLE 363 INDIA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 364 INDIA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 365 INDIA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 366 INDIA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 367 INDIA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 368 INDIA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 369 INDIA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 370 AUSTRALIA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 371 AUSTRALIA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 372 AUSTRALIA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 373 AUSTRALIA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 374 AUSTRALIA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 375 AUSTRALIA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)

TABLE 376 AUSTRALIA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 377 AUSTRALIA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)

TABLE 378 AUSTRALIA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 379 AUSTRALIA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 380 AUSTRALIA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 381 AUSTRALIA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 382 AUSTRALIA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 383 AUSTRALIA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 384 AUSTRALIA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 385 SINGAPORE PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 386 SINGAPORE WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 387 SINGAPORE WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 388 SINGAPORE ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 389 SINGAPORE SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 390 SINGAPORE PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)

TABLE 391 SINGAPORE PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 392 SINGAPORE PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)

TABLE 393 SINGAPORE PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 394 SINGAPORE PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 395 SINGAPORE CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 396 SINGAPORE DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 397 SINGAPORE DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 398 SINGAPORE PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 399 SINGAPORE PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 400 THAILAND PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 401 THAILAND WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 402 THAILAND WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 403 THAILAND ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 404 THAILAND SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 405 THAILAND PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)

TABLE 406 THAILAND PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 407 THAILAND PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)

TABLE 408 THAILAND PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 409 THAILAND PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 410 THAILAND CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 411 THAILAND DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 412 THAILAND DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 413 THAILAND PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 414 THAILAND PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 415 MALAYSIA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 416 MALAYSIA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 417 MALAYSIA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 418 MALAYSIA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 419 MALAYSIA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 420 MALAYSIA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)

TABLE 421 MALAYSIA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 422 MALAYSIA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)

TABLE 423 MALAYSIA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 424 MALAYSIA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 425 MALAYSIA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 426 MALAYSIA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 427 MALAYSIA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 428 MALAYSIA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 429 MALAYSIA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 430 INDONESIA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 431 INDONESIA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 432 INDONESIA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 433 INDONESIA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 434 INDONESIA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 435 INDONESIA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)

TABLE 436 INDONESIA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 437 INDONESIA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)

TABLE 438 INDONESIA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 439 INDONESIA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 440 INDONESIA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 441 INDONESIA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 442 INDONESIA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 443 INDONESIA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 444 INDONESIA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 445 PHILIPPINES PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 446 PHILIPPINES WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 447 PHILIPPINES WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 448 PHILIPPINES ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 449 PHILIPPINES SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 450 PHILIPPINES PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)

TABLE 451 PHILIPPINES PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 452 PHILIPPINES PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)

TABLE 453 PHILIPPINES PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 454 PHILIPPINES PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 455 PHILIPPINES CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 456 PHILIPPINES DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 457 PHILIPPINES DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 458 PHILIPPINES PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 459 PHILIPPINES PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 460 REST OF ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 461 SOUTH AMERICA PHARMACOGENETIC TESTING MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 462 SOUTH AMERICA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 463 SOUTH AMERICA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 464 SOUTH AMERICA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 465 SOUTH AMERICA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 466 SOUTH AMERICA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 467 SOUTH AMERICA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)

TABLE 468 SOUTH AMERICA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 469 SOUTH AMERICA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)

TABLE 470 SOUTH AMERICA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 471 SOUTH AMERICA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 472 SOUTH AMERICA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 473 SOUTH AMERICA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 474 SOUTH AMERICA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 475 SOUTH AMERICA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 476 SOUTH AMERICA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 477 BRAZIL PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 478 BRAZIL WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 479 BRAZIL WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 480 BRAZIL ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 481 BRAZIL SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 482 BRAZIL PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)

TABLE 483 BRAZIL PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 484 BRAZIL PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)

TABLE 485 BRAZIL PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 486 BRAZIL PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 487 BRAZIL CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 488 BRAZIL DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 489 BRAZIL DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 490 BRAZIL PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 491 BRAZIL PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 492 ARGENTINA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 493 ARGENTINA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 494 ARGENTINA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 495 ARGENTINA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 496 ARGENTINA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 497 ARGENTINA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)

TABLE 498 ARGENTINA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 499 ARGENTINA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)

TABLE 500 ARGENTINA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 501 ARGENTINA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 502 ARGENTINA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 503 ARGENTINA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 504 ARGENTINA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 505 ARGENTINA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 506 ARGENTINA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 507 REST OF SOUTH AMERICA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 508 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 509 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 510 MIDDLE EAST AND AFRICA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 511 MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 512 MIDDLE EAST AND AFRICA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 513 MIDDLE EAST AND AFRICA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 514 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)

TABLE 515 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 516 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)

TABLE 517 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 518 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 519 MIDDLE EAST AND AFRICA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 520 MIDDLE EAST AND AFRICA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 521 MIDDLE EAST AND AFRICA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 522 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 523 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 524 SOUTH AFRICA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 525 SOUTH AFRICA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 526 SOUTH AFRICA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 527 SOUTH AFRICA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 528 SOUTH AFRICA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 529 SOUTH AFRICA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)

TABLE 530 SOUTH AFRICA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 531 SOUTH AFRICA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)

TABLE 532 SOUTH AFRICA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 533 SOUTH AFRICA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 534 SOUTH AFRICA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 535 SOUTH AFRICA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 536 SOUTH AFRICA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 537 SOUTH AFRICA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 538 SOUTH AFRICA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 539 SAUDI ARABIA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 540 SAUDI ARABIA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 541 SAUDI ARABIA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 542 SAUDI ARABIA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 543 SAUDI ARABIA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 544 SAUDI ARABIA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)

TABLE 545 SAUDI ARABIA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 546 SAUDI ARABIA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)

TABLE 547 SAUDI ARABIA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 548 SAUDI ARABIA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 549 SAUDI ARABIA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 550 SAUDI ARABIA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 551 SAUDI ARABIA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 552 SAUDI ARABIA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 553 SAUDI ARABIA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 554 U.A.E. PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 555 U.A.E. WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 556 U.A.E. WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 557 U.A.E. ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 558 U.A.E. SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 559 U.A.E. PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)

TABLE 560 U.A.E. PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 561 U.A.E. PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)

TABLE 562 U.A.E. PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 563 U.A.E. PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 564 U.A.E. CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 565 U.A.E. DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 566 U.A.E. DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 567 U.A.E. PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 568 U.A.E. PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 569 ISRAEL PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 570 ISRAEL WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 571 ISRAEL WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 572 ISRAEL ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 573 ISRAEL SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 574 ISRAEL PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)

TABLE 575 ISRAEL PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 576 ISRAEL PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)

TABLE 577 ISRAEL PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 578 ISRAEL PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 579 ISRAEL CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 580 ISRAEL DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 581 ISRAEL DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 582 ISRAEL PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 583 ISRAEL PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 584 EGYPT PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 585 EGYPT WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 586 EGYPT WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 587 EGYPT ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 588 EGYPT SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 589 EGYPT PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)

TABLE 590 EGYPT PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 591 EGYPT PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)

TABLE 592 EGYPT PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)

TABLE 593 EGYPT PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 594 EGYPT CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 595 EGYPT DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 596 EGYPT DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 597 EGYPT PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 598 EGYPT PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 599 REST OF MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)